GSK2315698 (CPHPC)

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Amyloidosis

Phase 1

Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging

TerminatedNCT03417830

GlaxoSmithKlineAmyloidosis

Start: 2018-04-06End: 2018-07-20Updated: 2019-08-29

Phase 2

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

TerminatedNCT03044353

GlaxoSmithKlineAmyloidosis

Start: 2017-07-10End: 2019-01-03Updated: 2019-10-16

Related Papers

Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.

2022-02-1325 citations